Chimeric T Cell Receptors, Nucleic Acids, And Methods Of Making And Using The Same

Abstract: compositions and methods for eradicating tumor cells using novel compositions are contemplated. in one aspect, a pharmaceutical composition comprising a car scaffold and an antigen binding domain in a single chimeric species is provided. in some aspects, the car scaffold may comprise a cd28 costimulatory signaling region and a cd3� (activation domain or a complete cd3� activation domain. in some aspects, the car scaffold may be codon-optimized for improved expression in mammalian cell lines and/or for improved function upon transfection into natural killer (nk) or other immune cells. in further aspects, the antigen binding domain may comprise a vl and vh domain linked by a spacer and may be codon optimized. a cd leader sequence may be attached to the antigen binding domain, e.g., at the n-terminus of the antigen binding domain.

Inventor(s): Hermes GARBÁN

CPC Classification: C07K14/7051 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250206800